

What follows is a listing of clinical trials that are currently recruiting participants in the Houston area. It contains an extremely brief overview of the clinical trial's purpose and inclusion/exclusion criteria. We urge you to find complete information by looking up a study using its ID number at www.clinicaltrials.gov, or contacting the persons in charge of the study. Also, learn as much as possible about the clinical trial process, the risks involved, and your rights as a volunteer by reading our website or asking for fact sheets.

| Official Study Title | A few Inclusion Criteria | A few Exclusion Criteria | Contact Information | www.clinicaltrials.gov ID number |
|--|--|--|--|---|
| <p><i>Myriad Pharmaceuticals</i></p> <p>Phase III Study of daily treatment with MPC-7869 on cognitive ability and daily activities of patients with Alzheimer's Disease (AD).</p> | <p>Diagnosis of probable Alzheimer's Disease.</p> <p>Living in the community at time of enrollment (i.e., not living in a rest home of nursing care facility).</p> | <p>Current evidence of other causes of dementia.</p> <p>Chronic or acute renal, hepatic or metabolic disorder.</p> | <p>Teri Callaway 1-888-459-4888 teri.callaway@austin.ppd.com</p> <p>Mary L. Jackson, RN 1-888-459-4888 mjackson@myriad.com</p> <p>Trials are being conducted at both the University of Texas Mental Science Institute (UTMSI) and Baylor College of Medicine.</p> | <p>NCT00105547</p> |
| <p><i>Takeda Global Research & Development Center, Inc.</i></p> <p>Phase II Study on Rozerem 8 Mg (QHS), to study if patients with Alzheimer's Disease and sleep disturbance benefit from Rozerem.</p> | <p>The subject has at Visit 1 a history of at least 2 sleep disorder behaviors, occurring at least once weekly over past two weeks.</p> <p>Subject is residing in same home as primary caregiver</p> | <p>Subject is non-ambulatory.</p> <p>Subject is not living in the community (i.e., living in a rest home or nursing care facility).</p> <p>History of significant stroke or vascular dementia.</p> | <p>Teri Callaway, BS 512-685-5781 teri.callaway@austin.ppd.com</p> <p>Trials are being conducted in both Bellaire and Houston.</p> | <p>NCT00325728</p> |

Thanks to the National Institutes of Health for creating www.clinicaltrials.gov, a regularly updated resource for clinical trials across America. Also, thanks to the St. Louis Chapter for creating this table format for presenting a brief overview of clinical research.

| Official Study Title | A few Inclusion Criteria | A few Exclusion Criteria | Contact Information | www.clinicaltrials.gov ID number |
|--|---|--|---|--|
| <p><i>Elan Pharmaceuticals Wyeth</i></p> <p>Phase II study to assess the safety and tolerability of multiple doses of AAB-001 passive immunization in patients with mild to moderate Alzheimer's disease (AD).</p> | <p>Magnetic Resonance Imaging (MRI) scan consistent with diagnosis of AD</p> <p>Stable doses of medications</p> <p>Fluency in English</p> | <p>Weight greater than 120 kg (264 lbs)</p> <p>Anticonvulsants, Anti-Parkinson's, Anticoagulant, or Narcotic medications.</p> <p>Presence of pacemakers or foreign metal objects in eyes, skin, or body.</p> | <p>Baylor College of Medicine 6550 Fannin, Suite 1801 Houston, Texas, 77030</p> <p>Sayo Awosika-Olumo, MBBS, MPH 713-798-7433 olumo@bcm.tmc.edu</p> <p>Rachelle Doody, MD, Ph.D. Principal Investigator</p> | <p>NCT00112073</p> |
| <p><i>Voyager Pharmaceutical</i></p> <p><i>Information provided by National Institute on Aging (NIA).</i></p> <p>Phase III trial to investigate the activity of the hormone drug leuprolide acetate in stabilizing cognitive function in mild-to-moderate AD patients.</p> | <p>60 years of age or older</p> <p>No other significant or interfering medical conditions</p> <p>Diagnosis of probable mild-to-moderate Alzheimer's Disease</p> | <p>Significant neurological disease affecting the brain or psychiatric disease other than AD</p> <p>Laboratory or clinical signs of untreated, clinically significant abnormal thyroid function, in the Investigator's opinion</p> | <p>919-256-7512 trialinfo@voyagerpharma.com</p> <p>University of Texas Health Science Center at Houston 1300 Moursund Houston, TX 77030</p> <p>Saroj (Cindy) Kumar 713-500-2724 saroj.kumar@uth.tmc.edu</p> <p>Jary Lesser, M.D. Principal Investigator</p> | <p>NCT00231946</p> |

Thanks to the National Institutes of Health for creating www.clinicaltrials.gov, a regularly updated resource for clinical trials across America. Also, thanks to the St. Louis Chapter for creating this table format for presenting a brief overview of clinical research.

| Official Study Title | A few Inclusion Criteria | A few Exclusion Criteria | Contact Information | www.clinicaltrials.gov ID number |
|---|---|--|---|---|
| <p><i>Pfizer</i></p> <p>Phase III study to find out if the investigational study drug, Atorvastatin 80 MG, when taken with a cholinesterase inhibitor, is effective for treating Alzheimer's disease.</p> | <p>Diagnostic evidence of probable Alzheimer's disease consistent with NINCDS/ADRDA and DSM IV criteria</p> <p>Mini-Mental Status Examination Score (MMSE) must be in the range of 13 - 25 (inclusive) at Screening</p> | <p>Subjects with dementia due to causes other than Alzheimer's disease</p> <p>Any condition, which, in the investigator's judgment might increase the risk to the subject or decrease the reliability of the data required to meet study objectives.</p> | <p>Pfizer CT.gov Call Center 1-800-718-1021</p> <p>Trials are being conducted in Houston, Texas.</p> | <p>NCT00151502</p> |
| <p><i>Avanir Pharmaceuticals</i></p> <p>Phase III study to evaluate the safety of AVP-923 for the treatment of emotional lability (uncontrolled laughter and crying).</p> | <p>Clinical diagnosis of pseudobulbar affect.</p> <p>If female, must not be pregnant or breast feeding</p> | <p>Sensitivity to quinidine or any opiate drugs</p> <p>Current or prior history of major psychiatric disturbance</p> | <p>Methodist Neurological Institute 6560 Fannin Houston, Texas, 77030</p> <p>Joan Wilson, PA-C, CCRC 713-798-4073 joanew@bcm.tmc.edu</p> <p>Stanley H Appel, MD Principal Investigator</p> <p>Trial also in Bellaire, Texas.</p> | <p>NCT00277810</p> |

Thanks to the National Institutes of Health for creating www.clinicaltrials.gov, a regularly updated resource for clinical trials across America. Also, thanks to the St. Louis Chapter for creating this table format for presenting a brief overview of clinical research.

| Official Study Title | A few Inclusion Criteria | A few Exclusion Criteria | Contact Information | www.clinicaltrials.gov ID number |
|--|---|---|---|--|
| Both of the following trials are being offered by <i>Wyeth</i> , and are <u>currently recruiting</u> participants in Houston, Texas. | | | | |
| Phase II study to determine the safety, tolerability, and efficacy of 3 doses of lecozotan SR in patients with mild to moderate Alzheimer's Disease. | Diagnosis of probable AD according to the NINCDS-ADRDA criteria Able to give informed consent. | Use of medications for cognitive enhancement within 3 months of baseline. Significant neurological disease other than AD that may affect cognition | Trial Manager clintrialparticipation@wyeth.com | NCT00151398 |
| Phase II-III study to determine the safety, tolerability and efficacy of 3 doses of lecozotan in combination with a cholinesterase inhibitor in patients with mild to moderate Alzheimer's disease | Current use of cholinesterase inhibitor Diagnosis of probable Alzheimer's disease | Significant neurological disease other than AD History of stroke or other heart disease | Same as above | NCT00277810 |

Thanks to the National Institutes of Health for creating www.clinicaltrials.gov, a regularly updated resource for clinical trials across America. Also, thanks to the St. Louis Chapter for creating this table format for presenting a brief overview of clinical research.

| Official Study Title | A few Inclusion Criteria | A few Exclusion Criteria | Contact Information | www.clinicaltrials.gov ID number |
|--|--|--|---|--|
| <p><i>National Center for Research Resources (NCRR)</i> <i>Pfizer</i></p> <p>Phase I-II parallel design to determine if the anti-inflammatory agent ingested human recombinant interferon alpha (hrIFN-a) will inhibit the natural history of AD progression.</p> | <p>Possible or probable dementia of the Alzheimer Type defined by NINDS-ARDA criteria with dementia of at least one-year duration</p> <p>Adequate vision, hearing, speech, motor function and comprehension for compliance with all testing procedures</p> | <p>History of major psychiatric disorders; schizophrenia and unipolar or bipolar depression.</p> <p>Patients with known hypersensitivity to Donepezil HCL or other piperidine containing drugs</p> | <p>University of Texas - Houston Gerontology Center of the UTMSI 1300 Moursund Houston, Texas, 77030</p> <p>Staley A. Brod, M.D. Principal Investigator 713-500-7046 staley.a.brod@uth.tmc.edu</p> | <p>NCT00031018</p> |
| <p><i>National Institute on Aging (NIA)</i></p> <p>Alzheimer's Disease Neuroimaging Initiative</p> <p>To examine how brain imaging technology can be used with other tests to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's Disease</p> | <p>Permitted medications stable for at least 4 weeks prior to screening.</p> <p>Willing to undergo neuroimaging and provide DNA and plasma samples as specified</p> | <p>Any significant neurological disease other than Alzheimer's disease</p> <p>Abnormal baseline MRI</p> <p>Major depression, bipolar disorder, history of schizophrenia</p> | <p>Baylor College of Medicine 6550 Fannin, Suite 1801 Houston, Texas, 77030</p> <p>Lisa Greening, BS 713-798-5328 lgreenin@bcm.tmc.edu</p> <p>Rachelle Doody, MD, PhD, Principal Investigator</p> | <p>NCT00106899</p> |

Thanks to the National Institutes of Health for creating www.clinicaltrials.gov, a regularly updated resource for clinical trials across America. Also, thanks to the St. Louis Chapter for creating this table format for presenting a brief overview of clinical research.

| Official Study Title | A few Inclusion Criteria | A few Exclusion Criteria | Contact Information | www.clinicaltrials.gov ID number |
|--|--|---|---|---|
| <p><i>VA Medical Center, Houston Solvay Pharmaceuticals</i></p> <p>A Pilot Study of the Effect of Testosterone on Cerebral Glucose Metabolism in Hypogonadal Males With Mild Alzheimer's Disease</p> | <p>65 Years and above, and male</p> <p>Probable Alzheimer's disease diagnosis</p> <p>Right-handed</p> <p>Stable on concomitant medications for 1 month prior to starting study</p> | <p>Testosterone or other androgen treatment with in past 3 months</p> <p>History of prostate cancer</p> <p>Generalized skin disease that could affect the absorption of testosterone gel (ie, psoriasis)</p> <p>Sleep apnea</p> | <p>Robert S. Tan, MD 713-794-7382 Robert.Tan@va.gov</p> <p>Maurita Carrejo, MS 713-791-1414 Ext. 5245 Maurita.Carrejo@va.gov</p> <p>Michael E. DeBakey VA Medical Center, Houston, Texas, 77030</p> <p>Robert S. Tan, MD, Principal Investigator, Michael E. DeBakey VA Medical Center</p> | <p>NCT00392912</p> |
| <p><i>GlaxoSmithKline</i></p> <p>Previous research has shown that rosiglitazone, a diabetes drug, may have benefit in Alzheimer's patients and that this benefit may be related to a patient's genetic makeup. This study will test the efficacy and safety of rosiglitazone when added to standard approved drug treatment.</p> | <p>50 Years and above</p> <p>Clinical diagnosis of probable Alzheimer's Disease (AD).</p> <p>Have a regular caregiver.</p> | <p>Diagnosis of vascular dementia.</p> <p>Type 1 or secondary diabetes mellitus.</p> <p>Type II diabetes mellitus treated with insulin, sulfonylurea or flitinide.</p> | <p>GSK Clinical Trials Call Center, Houston, Texas, 77030; Recruiting Rachelle Doody 877-379-3718</p> <p>GSK Clinical Trials Call Center, Austin, Texas, 78757; Recruiting Jaron Winston 877-379-3718</p> | <p>NCT00348309</p> |

Thanks to the National Institutes of Health for creating www.clinicaltrials.gov, a regularly updated resource for clinical trials across America. Also, thanks to the St. Louis Chapter for creating this table format for presenting a brief overview of clinical research.

| Official Study Title | A few Inclusion Criteria | A few Exclusion Criteria | Contact Information | www.clinicaltrials.gov ID number |
|--|---|---|---|--|
| <p><i>Avanir Pharmaceuticals</i></p> <p>The purpose of this study is to evaluate the long-term safety of AVP-923 in the treatment of Involuntary Emotional Expression Disorder (IEED) also known as Pseudobulbar Affect (episodes of uncontrolled crying and/or laughter).</p> | <p>18 to 75 years of age, inclusive</p> <p>Clinical diagnosis of IEED (pseudobulbar affect)</p> <p>If female, must not be pregnant or breast feeding</p> | <p>Sensitivity to quinidine or any opiate drugs</p> <p>Current or prior history of major psychiatric disturbance</p> <p>Currently participated in a trial within the past 30 days</p> | <p>Methodist Neurological Institute, Houston, Texas, 77030; Recruiting Joan Appel, PA-C, CCRC 713-798-4073 joanew@bcm.tmc.edu Stanley H Appel, MD, Principal Investigator</p> <p>Claghorn-Lesem Research Clinic, Bellaire, Texas, 77401; Recruiting Debora Clay 713-665-6446 Michael Lesem, MD, Principal Investigator</p> | <p>NCT00056524</p> |
| <p><i>Partners in Dementia Care</i></p> <p>A care coordination and support service intervention for veterans with dementia and their family caregivers, delivered through partnerships between VA medical centers and local Alzheimer's Association Chapters.</p> | <p>Dementia Diagnosis, veteran, reside outside of a long-term care facility, live with local alzheimer Association chapter service of Houston, Oklahoma City, Boston, or Providence</p> | <p>Live in long-term care</p> | <p>VA Medical Center, Houston, Texas, 77030, United States; Recruiting Carol H Swartsfager (713) 794-8539 carols@bcm.tmc.edu</p> <p>Mark E Kunik, MD MPH (713) 794-8639 mkunik@bcm.tmc.edu</p> | <p>NCT00291161</p> |

Thanks to the National Institutes of Health for creating www.clinicaltrials.gov, a regularly updated resource for clinical trials across America. Also, thanks to the St. Louis Chapter for creating this table format for presenting a brief overview of clinical research.

| Official Study Title | A few Inclusion Criteria | A few Exclusion Criteria | Contact Information | www.clinicaltrials.gov ID number |
|--|--|--|---|---|
| <p><i>Open Label Study of the Effect of Daily Treatment With MPC-7869 in Subjects With Dementia of the Alzheimer's Type</i></p> <p>Open-label treatment with MPC-7869 for participants in a previous randomized study.</p> | <p>Participation in a previous MPC-7869 randomized protocol</p> <p>Have had a diagnosis of probable Alzheimer's disease.</p> <p>Men or women ages 55 years or greater.</p> | <p>History or evidence of, active malignancy, except for basal cell carcinoma or squamous cell carcinoma of the skin, within the 24 months prior to entry.</p> | <p>Sterlynn Mike 888-459-4888 smike@myriad.com</p> <p>Chris Clark, BS 888-459-4888 cclark@myriad.com</p> | <p>NCT00380276</p> |
| <p><i>A Randomized Double-Blind Placebo-Controlled Trial Of The Effects Of Docosahexaenoic Acid (DHA) In Slowing The Progression Of Alzheimer's Disease</i></p> <p>The purpose of this study is to determine whether chronic DHA (Docosahexaenoic Acid) supplementation slows the progression of cognitive and functional decline in mild to moderate Alzheimer's disease.</p> | <p>Male or female, 50 years of age or older</p> <p>Residing in the community at baseline</p> <p>Caregiver/study partner to accompany participant to all visits</p> <p>Able to ingest oral medication</p> | <p>Non-AD dementia</p> <p>Residence in a long-term care facility at baseline</p> <p>History of clinically significant stroke</p> | <p>Baylor University Department of Neurology, Houston, Texas, 77030, United States; Recruiting Jamie Sims, BS 713-798-5325 jsims@bcm.tmc.edu</p> <p>Lisa Lipscomb, RN 713-798-7431 lipscomb@bcm.tmc.edu</p> <p>Rachelle Doody, MD, PhD, Principal Investigator</p> | <p>NCT00440050</p> |

Thanks to the National Institutes of Health for creating www.clinicaltrials.gov, a regularly updated resource for clinical trials across America. Also, thanks to the St. Louis Chapter for creating this table format for presenting a brief overview of clinical research.